Leoncini, Mario <br/><br/>
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.  [electronic resource] 

 -  JACC. Cardiovascular interventions  Feb 2013 
 - 169-79 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1876-7605 
<br/><br/><label>Standard No.: </label>10.1016/j.jcin.2012.09.013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Atorvastatin<br/>Blood Platelets--drug effects<br/>Chi-Square Distribution<br/>Clopidogrel<br/>Coronary Artery Disease--blood<br/>Cytochrome P-450 CYP2C19<br/>Drug Interactions<br/>Drug Resistance<br/>Female<br/>Heptanoic Acids--administration & dosage<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--administration & dosage<br/>Italy<br/>Male<br/>Middle Aged<br/>Odds Ratio<br/>Percutaneous Coronary Intervention--adverse effects<br/>Pharmacogenetics<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Platelet Function Tests<br/>Prospective Studies<br/>Purinergic P2Y Receptor Antagonists--administration & dosage<br/>Pyrroles--administration & dosage<br/>Receptors, Purinergic P2Y12--blood<br/>Risk Assessment<br/>Risk Factors<br/>Ticlopidine--administration & dosage<br/>Time Factors<br/>Treatment Outcome